Forced to join the Waffen-SS? Chief pharmacist Victor Capesius (1907-1985) and his role in Auschwitz concentration camp.

Victor Capesius (1907-1985) attained sad fame as chief pharmacist in the Auschwitz concentration camp. After the war he outlined himself as a victim of his time and claimed to have been forced into the Waffen-SS as a so-called Romanian "Volksdeutscher" (ethnic German). But does this claim stand up to critical scrutiny? What was his actual role in Auschwitz, how did his life develop in the postwar period, how did he himself evaluate his actions in the Third Reich, and to what extent do self-image and historical facts coincide? These are precisely the questions that this article explores. The study is based on primary sources from various archives. These are supplemented and compared with the existing literature on Capesius, the role of pharmacists in the Third Reich, and the Auschwitz concentration camp.
The analysis shows that Capesius was not only complicit in the criminal acts in the concentration camp, but directly involved in the systematic killing of thousands of Jewish people - among other things, by dispensing Zyklon B and phenol and by the lethal selection of people at the ramp. The alleged compulsion to join the Waffen-SS, on the other hand, cannot be substantiated. After 1945, Capesius was imprisoned twice by the Allies, but only charged in the first Auschwitz trial in the 1960s. Despite a guilty verdict, he was released from prison as early as 1968. At the end of his life, Capesius could look back on a successful career as a pharmacist and businessman in Germany. At no time did he come to a self-critical evaluation of his role in the Third Reich.

Design, characterisation, and bioefficiency of insulin-chitosan nanoparticles after stabilisation by freeze-drying or cross-linking.

Insulin delivery by oral route would be ideal, but has no effect, due to the harsh conditions of the gastrointestinal tract. Protection of insulin using encapsulation in self-assembled particles is a promising approach. However, the lack of stability of this kind of particles in biological environments induces a low bioavailability of encapsulated insulin after oral administration. The objective of this work was to evaluate the effect of two stabilisation strategies alone or combined, freeze-drying and cross-linking, on insulin-loaded chitosan NPs, and to determine their bioefficiency in vitro and in vivo. NPs were prepared by complex coacervation between insulin and chitosan, stabilised either by cross linking with sodium tripolyphosphate solution (TPP), by freeze-drying or both treatments. In vitro bioefficiency NP uptake was evaluated by flow cytometry on epithelial models (Caco-2/RevHT29MTX (mucus secreting cells)). In vivo, NPs were injected via catheter in the peritoneum or duodenum on insulinopenic rats. Freeze-drying increased in size and charge (+15% vs control 412 ± 7 nm; + 36 ± 0.3 mV) in comparison with cross linking which decreased NP size (-25%) without impacting the NP charge. When combined the consecutive treatments reduced NPs size and increased charges as compared to standard level. Freeze drying is necessary to prevent the destruction of NP in intestinal environment in comparison with no freeze dryed one where 60% of NP were destroyed after 2h. Additionally freeze drying combined with cross linking treatments improved bioefficiency of NP with uptake in cell increased when mucus is present. Combination of both treatment showed a protection of insulin in vivo, with a reduction of glycemia when NPs were administrated. This work showed that the combination of freeze drying and cross linking treatment is necessary to stabilize (freeze-drying) and increase bioefficiency (cross-linking) of self assembled NP in the delivery of insulin in vitro and in vivo.